PeptiGrowth

Tokyo, Japan· Est. 2020

Develops synthetic peptide alternatives to growth factors for xeno-free cell culture in regenerative medicine.

peptigrowth.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

Develops synthetic peptide alternatives to growth factors for xeno-free cell culture in regenerative medicine.

Metabolic

Technology Platform

Utilizes PeptiDream's PeptiDream Discovery Platform System (PDPS) to discover and develop macrocyclic peptides that functionally mimic natural protein growth factors by binding to and activating specific cell surface receptors.

Opportunities

Significant growth opportunity driven by the rapid expansion of the cell and gene therapy market, which requires defined, xeno-free culture components for scalable and compliant manufacturing.

Potential to expand platform into novel therapeutic peptides.

Risk Factors

Dependence on PeptiDream's PDPS technology; competition from established life science tools companies producing recombinant growth factors; market adoption risk as cell therapy developers may be slow to change validated media formulations.

Competitive Landscape

Competes with recombinant protein divisions of large life science suppliers (Thermo Fisher, Merck) and specialized media companies. Differentiation lies in a comprehensive portfolio of synthetic, chemically-defined peptide alternatives offering potentially superior consistency and lower immunogenicity risk.

More companies in Japan →